Michael B. Chancellor - 13 Mar 2024 Form 4 Insider Report for LIPELLA PHARMACEUTICALS INC. (LIPO)

Reporting relationship: Chief Medical Officer, Director, 10%+ Owner
Issuer ticker: LIPO
Reported as of: 13 Mar 2024
Net transaction value: +$100,000
SEC form: 4
Accepted by SEC: 15 Mar 2024, 12:19:19 UTC
Prior SEC filing: 21 Jun 2023
Next SEC filing: 19 Mar 2024
Source filing: View source filing
Reporting owner signature: /s/ Michael B. Chancellor

Filing notes and source

Key filing fact

Michael B. Chancellor filed Form 4 for LIPELLA PHARMACEUTICALS INC. (LIPO) on 15 Mar 2024.

Key facts

This page summarizes Michael B. Chancellor's Form 4 filing for LIPELLA PHARMACEUTICALS INC. (LIPO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 15 Mar 2024, 12:19.

Change

Previous filing in this sequence was filed on 21 Jun 2023.
Current net transaction value: +$100,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LIPO transaction

Common Stock

Award

Transaction value: $100,000
Shares: +144,906
Change %: +20%
Price: $0.6901
Shares after: 877,637
Date: 13 Mar 2024
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The number of shares of Common Stock has been increased by one from the number of shares reported as directly owned in the Form 4 filed by the reporting person on December 27, 2022 in order to correct an inadvertent administrative error in such prior Form 4.